RxDoctor Payments Data

Michalene Torbik, DO

Family Medicine · Pittston, PANPI 1578561023

Payments from drug & device makers

$7,145in general payments, 2019–2025

Across 448 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$912
  • Pfizer$831
  • Novo Nordisk$827
  • Amgen$797
  • Lilly USA, LLC$676
  • GSK$589
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,126100%
  • Education$60%
  • Gifts$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,145 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$168,143
Medicare patients
566
Services billed
2,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$187,591
OzempicSemaglutide100$107,490
JanuviaSitagliptin Phosphate128$61,247
FingolimodFingolimod Hcl12$58,874
XareltoRivaroxaban114$55,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$46,834
MounjaroTirzepatide31$31,658
JardianceEmpagliflozin77$30,212
TradjentaLinagliptin28$24,035
Breo ElliptaFluticasone/Vilanterol40$23,608
Atorvastatin Calcium1,458$13,453
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,811
JanumetSitagliptin Phos/Metformin Hcl17$11,988
Levothyroxine Sodium1,319$11,430
TrulicityDulaglutide15$11,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$831$187,591342 claims
Novo NordiskOzempic$827$107,490100 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$589$83,253120 claims
MerckJanuvia, Janumet$14$73,235145 claims
Johnson & JohnsonXarelto$27$55,215114 claims
Boehringer IngelheimJardiance, Tradjenta$60$54,247105 claims
Lilly USA, LLCMounjaro, Trulicity$676$42,99846 claims
AbbVieCreon, Synthroid$912$15,235109 claims
NovartisEntresto$109$5,42912 claims
AstraZenecaBrilinta$531$4,88923 claims
Almatica Pharma LLCSertraline Hcl$45$4,376434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →